Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.
Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Schelter BO, Wischik DJ, Davis CS, Staff RT, Vuksanovic V, Ahearn T, Bracoud L, Shamsi K, Marek K, Seibyl J, Riedel G, Storey JMD, Harrington CR, Wischik CM.
Wilcock GK, et al. Among authors: wischik cm, wischik dj.
J Alzheimers Dis. 2018;61(1):435-457. doi: 10.3233/JAD-170560.
J Alzheimers Dis. 2018.
PMID: 29154277
Free PMC article.
Clinical Trial.